NASDAQ:LIFEaTyr Pharma Stock Price, Forecast & News

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LIFE shares have increased by 36.0% and is now trading at $4.12. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for aTyr Pharma.

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for aTyr Pharma.

aTyr Pharma Inc (NASDAQ:LIFE) released its earnings results on Tuesday, May, 12th. The biotechnology company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.43. The biotechnology company had revenue of $8.07 million for the quarter, compared to the consensus estimate of $4.40 million. aTyr Pharma had a negative net margin of 185.14% and a negative return on equity of 52.40%. View aTyr Pharma's earnings history.

aTyr Pharma's stock reverse split on the morning of Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

4 analysts have issued 12 month price targets for aTyr Pharma's shares. Their forecasts range from $4.00 to $15.00. On average, they anticipate aTyr Pharma's share price to reach $8.75 in the next twelve months. This suggests a possible upside of 112.4% from the stock's current price. View analysts' price targets for aTyr Pharma.

Media stories about LIFE stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. aTyr Pharma earned a news impact score of -2.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutaTyr Pharma.

Some companies that are related to aTyr Pharma include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and BG Medicine (BGMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD), Idera Pharmaceuticals (IDRA), Johnson & Johnson (JNJ) and Precigen (PGEN).

(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

aTyr Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (17.27%), Alyeska Investment Group L.P. (7.89%), Viking Global Investors LP (6.28%), Two Sigma Investments LP (0.69%), UBS Group AG (0.41%) and Two Sigma Advisers LP (0.39%). Company insiders that own aTyr Pharma stock include Jill Marie Broadfoot, John Mendlein, Nancy Krueger and Paul Schimmel. View institutional ownership trends for aTyr Pharma.

LIFE stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Alyeska Investment Group L.P., Viking Global Investors LP, Two Sigma Investments LP, Two Sigma Advisers LP, UBS Group AG, Oppenheimer & Co. Inc., and Marquette Asset Management LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, John Mendlein, and Paul Schimmel. View insider buying and selling activity for aTyr Pharma.

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LIFE stock can currently be purchased for approximately $4.12.

aTyr Pharma has a market capitalization of $38.52 million and generates $420,000.00 in revenue each year. The biotechnology company earns $-23,600,000.00 in net income (profit) each year or ($7.03) on an earnings per share basis. aTyr Pharma employs 42 workers across the globe.

The official website for aTyr Pharma is www.atyrpharma.com.

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]